Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 17.30B +37.9% |
| Revenue (ttm) | 3.10B +28.6% |
| Net Income | 668.60M +118.6% |
| EPS | 6.50 +119.9% |
| Shares Out | 100.55M |
| PE Ratio | 26.77 |
| Forward PE | 16.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,032,668 |
| Open | 177.33 |
| Previous Close | 174.10 |
| Day's Range | 169.04 - 177.33 |
| 52-Week Range | 122.14 - 181.18 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 198.95 (+15.64%) |
| Earnings Date | Jul 30, 2026 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for NBIX stock is "Strong Buy." The 12-month stock price target is $198.95, which is an increase of 15.64% from the latest price.
News
Neurocrine price target raised to $200 from $155 at Truist
Truist raised the firm’s price target on Neurocrine (NBIX) to $200 from $155 and keeps a Buy rating on the shares as part of a broader research note previewing Q2…
Neurocrine price target raised to $170 from $144 at BMO Capital
BMO Capital raised the firm’s price target on Neurocrine (NBIX) to $170 from $144 and keeps a Market Perform rating on the shares as part of a broader research note…
Neurocrine price target raised to $185 from $176 at Wedbush
Wedbush raised the firm’s price target on Neurocrine (NBIX) to $185 from $176 and keeps an Outperform rating on the shares. The firm updated its model ahead of the Q2…
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter...
Neurocrine price target raised to $195 from $183 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Neurocrine (NBIX) to $195 from $183 and keeps an Outperform rating on the shares as part of a broader…
Neurocrine initiates Phase 2 study of crinecerfont
Neurocrine (NBIX) Biosciences announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with…
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont i...
Neurocrine price target raised to $208 from $182 at UBS
UBS raised the firm’s price target on Neurocrine (NBIX) to $208 from $182 and keeps a Buy rating on the shares. Neurocrine is a value-oriented biotech whose near-term performance may…
Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
Soleno Therapeutics, a Neurocrine (NBIX) Biosciences company, announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT XR extended-release tablets for two years after a 16-...
Neurocrine presents first retrospective case series of Crenessity
Neurocrine (NBIX) Biosciences announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia due to 11beta-hydroxylase...
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing throug...
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Neurocrine presents two-year Crenessity data
Neurocrine (NBIX) Biosciences announced new Phase 3 CAHtalyst Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year data showed that pediatric patients with accelerated bone age at baseline experienced slowed bone age progression and improved predicted adult height with CRENESSITY Cross-sectional caregiver...
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among p...
Neurocrine Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has evolved into a multi-product leader with strong revenue growth from INGREZZA, CRENESSITY, and VYKAT XR, supported by strategic acquisitions and a robust R&D pipeline. Key pipeline assets are set for major data readouts in 2027–2028, while ongoing investments in sales force and market education drive adoption and future growth.
Neurocrine reports new post-hoc data from KINECT 4 trial
Neurocrine (NBIX) Biosciences announced new post-hoc data from the KINECT 4 clinical trial demonstrating that adults with tardive dyskinesia treated with INGREZZA capsules experienced clinically meani...
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients
New 48-week KINECT® 4 post-hoc analysis shows 94% of participants treated with INGREZZA achieved either symptomatic remission or a clinically meaningful response (≥30% reduction from baseline in Abnor...
Neurocrine presents new data showing Improvements with INGREZZA
Neurocrine (NBIX) Biosciences announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia s...
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those, 89% experienced improvement within...
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Analyses span adult and pediatric populations with classic congenital adrenal hyperplasia (CAH) and reflect longer-term clinical outcomes relevant to disease management across lifespan and care contin...
Neurocrine Biosciences Transcript: 46th Annual William Blair Growth Stock Conference
Significant transformation to a multi-product, high-growth company with strong cash flow and diversified revenue. Recent acquisition of Soleno Therapeutics expands the rare endocrine franchise, while robust R&D investment supports a broad pipeline and future growth.
Neurocrine reinstated with a Buy at Goldman Sachs
Goldman Sachs reinstated coverage of Neurocrine (NBIX) with a Buy rating and $213 price target The completion of the Soleno Therapeutics acquisition bolsters the company’s medium-term revenue growth t...
Neurocrine price target raised to $183 from $180 at RBC Capital
RBC Capital raised the firm’s price target on Neurocrine (NBIX) to $183 from $180 and keeps an Outperform rating on the shares. Shares have rebounded following a strong Q1, though…